Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.

Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7

Studie: TMK; Indikation: Mammakarzinom; Jahr: 2017; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com